Table 2.
Results of univariate analysis of PFS and OS
| Covariate | PFS, years | OS, years | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age, years | ||||
| ≥ 70 | 1.03 (0.74–1.44) | 0.844 | 1.58 (1.10–2.29) | 0.015* |
| < 70 | 1 (Ref) | 1 (Ref) | ||
| Sex | ||||
| Male | 1.30 (0.85–1.98) | 0.224 | 1.06 (0.64–1.74) | 0.826 |
| Female | 1 (Ref) | 1 (Ref) | ||
| Smoking status | ||||
| ≥ 20 pack/year | 1.44 (1.03–2.02) | 0.035* | 1.36 (0.90–2.07) | 0.145 |
| < 20 pack/year | 1 (Ref) | 1 (Ref) | ||
| BMI | ||||
| ≥ 24 | 0.96 (0.70–1.31) | 0.793 | 0.71 (0.48–1.04) | 0.075 |
| < 18.5 | 0.91 (0.51–1.60) | 0.747 | 0.93 (0.45–1.93) | 0.848 |
| 18.5–23.9 | 1 (Ref) | 1 (Ref) | ||
| ECOG score | ||||
| ≥ 2 | 0.82 (0.49–1.37) | 0.445 | 1.05 (0.59–1.88) | 0.860 |
| 0–1 | 1 (Ref) | 1 (Ref) | ||
| T | ||||
| T3–4 | 1.04 (0.78–1.38) | 0.802 | 1.01 (0.71–1.44) | 0.941 |
| T1–2 | 1 (Ref) | 1 (Ref) | ||
| N | ||||
| N1–3 | 1.53 (0.85–2.76) | 0.161 | 1.27 (0.65–2.51) | 0.484 |
| N0 | 1 (Ref) | 1 (Ref) | ||
| M | ||||
| M1 | 1.46 (1.09–1.95) | 0.010* | 1.31 (0.92–1.86) | 0.128 |
| M0 | 1 (Ref) | 1 (Ref) | ||
| First-line CT | ||||
| EP/EC | 0.80 (0.35–1.82) | 0.597 | 0.43 (0.16–1.17) | 0.163 |
| IP/IC | 0.82 (0.27–2.44) | 0.717 | 0.34 (0.08–1.54) | |
| Others | 1 (Ref) | 1 (Ref) | ||
| Prior radiotherapy | ||||
| Yes | 0.75 (0.57–1.01) | 0.054 | 0.67 (0.47–0.96) | 0.030* |
| No | 1 (Ref) | 1 (Ref) | ||
| Tumor burden | ||||
| > 8 cm | 0.98 (0.94–1.02) | 0.233 | 0.98 (0.93–1.02) | 0.308 |
| ≤ 8 cm | 1 (Ref) | 1 (Ref) | ||
| TSR | ||||
| ≥ − 6.6% | 1.10 (1.06–1.13) | 1.25E−08* | 1.11 (1.07–1.15) | 1.14E−07* |
| < − 6.6% | 1 (Ref) | 1 (Ref) | ||
BMI: body mass index; CI: confidence interval; ECOG: Eastern Cooperative Oncology Group; EP: cisplatin + etoposide; HR: hazard ratio; IC: irinotecan + cisplatin; IP: irinotecan + carboplatin; OS: overall survival; PFS: progression-free survival; TSR: tumor shrinkage rate